CHIEF-HF

	Janssen CHIEF-HF Patient Information Video
Scene ID	**Audio Transcript**
01	CHIEF-HF is a virtual study that will evaluate an investigational medicine for heart failure.
02	Based on your medical history, you may qualify to participate.
03	As this is a virtual study, you will not attend any hospital or clinic visits, but you may still see your regular doctor while participating.
04	During the study, your data will be collected using both a smartphone device and a Fitbit device.
05	The Fitbit device will be provided for you to use in this study.
06	The data that is collected will include questionnaires, Fitbit data (e.g. step count), medication information, and healthcare claims.
07	Before you can begin the CHIEF-HF study, you must first give your permission.
08	On the CHIEF-HF study app, which you will download on your smartphone device, you can view the eConsent form. This is an informed consent form that must be signed electronically before you can take part in the study.
09	The eConsent form outlines the aim of the study, how it will be performed, and the potential benefits and risks associated with the study.
10	Participation is voluntary and you can choose to withdraw from the study at any time.
11	If you decide to withdraw from the study, you should contact a member of the Support Team to discuss your options.
12	If you have any questions about the study, you will have the chance to speak with your principal investigator (PI) who can answer these questions before you sign the eConsent form.
13	After you are enrolled in the study, you can contact your Support Team at any time.
14	To be eligible to take part, you must be 18 years of age or older, have heart failure, and own a smartphone device.
15	Your smartphone device must be compatible with a Fitbit, which you must be willing to wear for 9 months.
16	Some of the reasons you will not be able to take part in the study include: having type 1 diabetes or chronic kidney disease, or having had a major surgery within the past 3 months.
17	Your medical records will also be accessed to confirm if you are eligible for the study, and to collect additional medical information.
18	The medical records will only be accessed as required.
19	After you have been confirmed for study participation, you will be randomly assigned to receive either the investigational study drug or placebo.
20	Placebo looks identical to the investigational study drug, but it does not contain any active medication.
21	For the first 3 months of the study, you will take your assigned study treatment daily.
22	During this period, you will wear the Fitbit to measure your level of daily activity.
23	You will also complete a number of questionnaires that will help to assess your health and quality of life.
24	From Months 3 to 9 (which is the end of the study), you will not receive the study drug or placebo, but you will continue to wear the Fitbit, and complete questionnaires.
25	Throughout the study, if you experience any side effects, you will report them to a study team member by contacting the Support Team.